Quantum Cyber N.V. (QUCY)
QUCY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1874252/000121390026037676/0001213900-26-037676-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | QUCY on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Germany |
| IPO year | 2021 |
| SEC CIK | 0001874252 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Netherlands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $537K |
| Net income | -$16.2M |
| Operating income | -$16.1M |
| Net margin | -3018.3% |
| Operating margin | -3005.0% |
| Revenue growth | -39.9% |
| Cash | $889K |
| Total assets | $5.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 95.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raised substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued." | 10-Q 2026-11-12 |
| Cash and burn | $4.9M cash; operating cash flow -$4.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 87,241,735 (2026-11-12); 21,165,482 three years earlier. | Cover page 2026-11-12 |
| Reverse splits, 3 years | 1; latest on 2026-04-28 | Source 2026-04-28 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 4 424B5 takedowns, 3 at the market | Latest 2026-10-09 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-03-25 |
| Auditor | Reliant CPA PC, Newport Beach, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-06-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $967K | -$5.4M | -$4.3M | $4.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$11.0M | -$7.2M | $13.4M | $169K | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$5.1M | -$2.7M | $4.7M | $127K | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$4.8M | -$1.7M | $889K | $2.2M | $537K | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$2.9M | -$2.6M | $1.0M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$3.5M | -$2.7M | $1.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$5.0M | -$3.9M | $1.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-10-09 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-31 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-13 |
| Latest proxy DEFINITIVE PROXY STATEMENT | DEF 14A | 2026-06-01 |
Source: SEC EDGAR submissions feed, 207 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.3% |
| 1 month | -43.5% |
| 3 months | -55.4% |
| Year to date | -43.5% |
| 1 year | -56.6% |
| From 52-week high | -82.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RFL | Rafael Holdings Inc. | $0.9701 | -9.34% | $50.6M |
| SDEV | Stablecoin Development Corporation | $0.7055 | -9.55% | $51.6M |
| APLM | Apollomics Inc. | $17.84 | +0.91% | $51.7M |
| IBIO | iBio Inc. | $0.7067 | -3.42% | $49.8M |
| CTOR | Citius Oncology Inc. | $0.5350 | -6.76% | $49.7M |
| CLNN | Clene Inc. | $3.66 | -6.63% | $52.7M |
| MREO | Mereo BioPharma Group plc | $0.3050 | -0.81% | $48.7M |
| HOWL | Werewolf Therapeutics Inc. | $0.9908 | +1.07% | $48.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier